Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Lohmann

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2020
Early Treatment Response Assessment Using <sup>18</sup>F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide ChemotherapyGarry Ceccon, Philipp Lohmann, Jan-Michael Werner, et al.
Cancers|July 29, 2023
Hybrid PET/MRI in Cerebral Glioma: Current Status and PerspectivesKarl-Josef Langen, Norbert Galldiks, Jörg Mauler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 26, 2020
Sequential implementation of DSC-MR perfusion and dynamic [<sup>18</sup>F]FET PET allows efficient differentiation of glioma progression from treatment-related changesEike Steidl, Karl-Josef Langen, Sarah Abu Hmeidan, et al.
Neuro-Oncology|May 12, 2019
Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patientsNorbert Galldiks, Marcus Unterrainer, Natalie Judov, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2025
An External, Independent Validation of an <i>O</i>-(2-[<sup>18</sup>F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with GlioblastomaNathaniel Barry, Jake Kendrick, Pejman Rowshanfarzad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 2, 2020
Flare Phenomenon in <i>O</i>-(2-<sup>18</sup>F-Fluoroethyl)-l-Tyrosine PET After Resection of GliomasChristian P Filss, Ann K Schmitz, Gabriele Stoffels, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 9, 2018
Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustineNorbert Galldiks, Veronika Dunkl, Garry Ceccon, et al.
Neuro-Oncology|July 30, 2016
Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapyGarry Ceccon, Philipp Lohmann, Gabriele Stoffels, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 26, 2023
Diagnostic Accuracy of MR Spectroscopic Imaging and <sup>18</sup>F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI StudyJörg Mauler, Philipp Lohmann, Andrew A Maudsley, et al.
Scientific Reports|September 8, 2018
Predicting IDH genotype in gliomas using FET PET radiomicsPhilipp Lohmann, Christoph Lerche, Elena K Bauer, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2020
Early Treatment Response Assessment Using <sup>18</sup>F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide ChemotherapyGarry Ceccon, Philipp Lohmann, Jan-Michael Werner, et al.
Cancers|July 29, 2023
Hybrid PET/MRI in Cerebral Glioma: Current Status and PerspectivesKarl-Josef Langen, Norbert Galldiks, Jörg Mauler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 26, 2020
Sequential implementation of DSC-MR perfusion and dynamic [<sup>18</sup>F]FET PET allows efficient differentiation of glioma progression from treatment-related changesEike Steidl, Karl-Josef Langen, Sarah Abu Hmeidan, et al.
Neuro-Oncology|May 12, 2019
Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patientsNorbert Galldiks, Marcus Unterrainer, Natalie Judov, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2025
An External, Independent Validation of an <i>O</i>-(2-[<sup>18</sup>F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with GlioblastomaNathaniel Barry, Jake Kendrick, Pejman Rowshanfarzad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 2, 2020
Flare Phenomenon in <i>O</i>-(2-<sup>18</sup>F-Fluoroethyl)-l-Tyrosine PET After Resection of GliomasChristian P Filss, Ann K Schmitz, Gabriele Stoffels, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 9, 2018
Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustineNorbert Galldiks, Veronika Dunkl, Garry Ceccon, et al.
Neuro-Oncology|July 30, 2016
Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapyGarry Ceccon, Philipp Lohmann, Gabriele Stoffels, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 26, 2023
Diagnostic Accuracy of MR Spectroscopic Imaging and <sup>18</sup>F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI StudyJörg Mauler, Philipp Lohmann, Andrew A Maudsley, et al.
Scientific Reports|September 8, 2018
Predicting IDH genotype in gliomas using FET PET radiomicsPhilipp Lohmann, Christoph Lerche, Elena K Bauer, et al.
Pageof 14